New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3

키워드

참고문헌 (71)

1. Roth GA, "Global burden of cardiovascular diseases and risk factors, 1990-2019 : update from the GBD 2019 study", J Am Coll Cardiol, 76, pp.2982~3021 (2020)
2. Pol T, "Dyslipidemia and risk of cardiovascular events in patients with atrial fibrillation treated with oral anticoagulation therapy : insights from the ARISTOTLE(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)trial", J Am Heart Assoc, 7, pp.e007444~ (2018)
3. Sharrett AR, "Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions : the Atherosclerosis Risk in Communities(ARIC)Study", Circulation, 104, pp.1108~1113 (2001)
4. Mortensen MB, "Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years : a contemporary primary prevention cohort", Lancet, 396, pp.1644~1652 (2020)
5. Steinbrecher UP, "Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids", Proc Natl Acad Sci U S A, 81, pp.3883~3887 (1984)
6. Ross R, "The pathogenesis of atherosclerosis : a perspective for the 1990s", Nature, 362, pp.801~809 (1993)
7. Goldstein JL, "The LDL receptor", Arterioscler Thromb Vasc Biol, 29, pp.431~438 (2009)
8. Ross SD, "Clinical outcomes in statin treatment trials : a meta-analysis", Arch Intern Med, 159, pp.1793~1802 (1999)
9. Karatasakis A, "Effect of PCSK9inhibitors on clinical outcomes in patients with hypercholesterolemia : a meta-analysis of 35 randomized controlled trials", J Am Heart Assoc, 6, pp.e006910~ (2017)
10. Silverman MG, "Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions : a systematic review and meta-analysis", JAMA, 316, pp.1289~1297 (2016)
11. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
12. Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
13. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
14. Fruchart JC, "The Residual Risk Reduction Initiative : a call to action to reduce residual vascular risk in patients with dyslipidemia", Am J Cardiol, 102, pp.1K~34K (2008)
15. Kwiterovich PO Jr, "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides : a current review", Am J Cardiol, 86, pp.5L~10L (2000)
16. Grundy SM, "Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome", Am J Cardiol, 81, pp.18B~25B (1998)
17. Mooradian AD, "Dyslipidemia in type 2 diabetes mellitus", Nat Clin Pract Endocrinol Metab, 5, pp.150~159 (2009)
18. Kannel WB, "Lipids, diabetes, and coronary heart disease : insights from the Framingham Study", Am Heart J, 110, pp.1100~1107 (1985)
19. Sarwar N, "Triglycerides and the risk of coronary heart disease : 10, 158 incident cases among 262, 525 participants in 29 Western prospective studies", Circulation, 115, pp.450~458 (2007)
20. Packard CJ, "Causes and consequences of hypertriglyceridemia", Front Endocrinol(Lausanne), 11, pp.252~ (2020)
21. Nordestgaard BG, "Triglycerides and cardiovascular disease", Lancet, 384, pp.626~635 (2014)
22. Proctor SD, "Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy", Arterioscler Thromb Vasc Biol, 24, pp.2162~2167 (2004)
23. Proctor SD, "Arterial retention of apolipoprotein B(48)-and B(100)-containing lipoproteins in atherogenesis", Curr Opin Lipidol, 13, pp.461~470 (2002)
24. Do R, "Common variants associated with plasma triglycerides and risk for coronary artery disease", Nat Genet, 45, pp.1345~1352 (2013)
25. Varbo A, "Remnant cholesterol as a causal risk factor for ischemic heart disease", J Am Coll Cardiol, 61, pp.427~436 (2013)
26. Ference BA, "Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease", JAMA, 321, pp.364~373 (2019)
27. Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus(the FIELD study) : randomised controlled trial", Lancet, 366, pp.1849~1861 (2005)
28. ACCORD Study Group, "Effects of combination lipid therapy in type 2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
29. Bhatt DL, "Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia", N Engl J Med, 380, pp.11~22 (2019)
30. Sheikh O, "Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial", Cardiovasc Diabetol, 18, pp.84~ (2019)
31. Graham MJ, "Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans", Circ Res, 112, pp.1479~1490 (2013)
32. Digenio A, "Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes", Diabetes Care, 39, pp.1408~1415 (2016)
33. Witztum JL, "Volanesorsen and triglyceride levels in familial chylomicronemia syndrome", N Engl J Med, 381, pp.531~542 (2019)
34. Gouni-Berthold I, "Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia(COMPASS) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Diabetes Endocrinol, 9, pp.264~275 (2021)
35. Alexander VJ, "N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels", Eur Heart J, 40, pp.2785~2796 (2019)
36. Dewey FE, "Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease", N Engl J Med, 377, pp.211~221 (2017)
37. Ahmad Z, "Inhibition of angiopoietinlike protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia", Circulation, 140, pp.470~486 (2019)
38. Rosenson RS, "Evinacumab in patients with refractory hypercholesterolemia", N Engl J Med, 383, pp.2307~2319 (2020)
39. Rosenson RS, "A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia", Atherosclerosis, 331, pp.e293~ (2021)
40. Raal FJ, "Evinacumab for homozygous familial hypercholesterolemia", N Engl J Med, 383, pp.711~720 (2020)
41. Graham MJ, "Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides", N Engl J Med, 377, pp.222~232 (2017)
42. Gaudet D, "Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia", Eur Heart J, 41, pp.3936~3945 (2020)
43. Kohan AB, "Apolipoprotein C-III : a potent modulator of hypertriglyceridemia and cardiovascular disease", Curr Opin Endocrinol Diabetes Obes, 22, pp.119~125 (2015)
44. Ginsberg HN, "Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo", J Clin Invest, 78, pp.1287~1295 (1986)
45. Gordts PL, "ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors", J Clin Invest, 126, pp.2855~2866 (2016)
46. Sundaram M, "Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions", J Lipid Res, 51, pp.150~161 (2010)
47. Mendoza S, "Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions", J Clin Lipidol, 11, pp.224~233 (2017)
48. Zvintzou E, "Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity", J Lipid Res, 58, pp.1869~1883 (2017)
49. Kawakami A, "Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein-and protein kinase C alphamediated nuclear factor-kappaB activation", Arterioscler Thromb Vasc Biol, 27, pp.219~225 (2007)
50. Olivieri O, "ApoC-III gene polymorphisms and risk of coronary artery disease", J Lipid Res, 43, pp.1450~1457 (2002)
51. Pollin TI, "A null mutation in human APOC3confers a favorable plasma lipid profile and apparent cardioprotection", Science, 322, pp.1702~1705 (2008)
52. Jørgensen AB, "Loss-of-function mutations in APOC3 and risk of ischemic vascular disease", N Engl J Med, 371, pp.32~41 (2014)
53. Dias N, "Antisense oligonucleotides : basic concepts and mechanisms", Mol Cancer Ther, 1, pp.347~355 (2002)
54. Paik J, "Volanesorsen : first global approval", Drugs, 79, pp.1349~1354 (2019)
55. Lüscher TF, "Frontiers in lipid research : lipoprotein(a), apolipoprotein C-III and E, and PCSK9 and inflammation", Eur Heart J, 40, pp.2741~2744 (2019)
56. Khetarpal SA, "A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels", Nat Med, 23, pp.1086~1094 (2017)
57. Kettunen S, "RNA interference-based therapies for the control of atherosclerosis risk factors", Curr Opin Cardiol, 37, pp.364~371 (2022)
58. Conklin D, "Identification of a mammalian angiopoietin-related protein expressed specifically in liver", Genomics, 62, pp.477~482 (1999)
59. Kersten S, "Angiopoietin-like 3 in lipoprotein metabolism", Nat Rev Endocrinol, 13, pp.731~739 (2017)
60. Shimizugawa T, "ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase", J Biol Chem, 277, pp.33742~33748 (2002)
61. Koishi R, "Angptl3 regulates lipid metabolism in mice", Nat Genet, 30, pp.151~157 (2002)
62. Quagliarini F, "Atypical angiopoietin-like protein that regulates ANGPTL3", Proc Natl Acad Sci U S A, 109, pp.19751~19756 (2012)
63. Chi X, "ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase", Mol Metab, 6, pp.1137~1149 (2017)
64. Jaye M, "A novel endothelial-derived lipase that modulates HDL metabolism", Nat Genet, 21, pp.424~428 (1999)
65. Shimamura M, "Angiopoietin-like protein3regulates plasma HDL cholesterol through suppression of endothelial lipase", Arterioscler Thromb Vasc Biol, 27, pp.366~372 (2007)
66. Adam RC, "Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance", J Lipid Res, 61, pp.1271~1286 (2020)
67. Musunuru K, "Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia", N Engl J Med, 363, pp.2220~2227 (2010)
68. Stitziel NO, "ANGPTL3 deficiency and protection against coronary artery disease", J Am Coll Cardiol, 69, pp.2054~2063 (2017)
69. Gusarova V, "ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys", J Lipid Res, 56, pp.1308~1317 (2015)
70. Markham A, "Evinacumab : first approval", Drugs, 81, pp.1101~1105 (2021)
71. Crooke ST, "Integrated assessment of the clinical performance of GalNAc3-conjugated 2′-O-methoxyethyl chimeric antisense oligonucleotides : I. Human volunteer experience", Nucleic Acid Ther, 29, pp.16~32 (2019)

관련 논문AI추천